Navigation Links
DelMar Pharmaceuticals Presents Interim Phase 1/2 Clinical Data for VAL-083 in Glioblastoma at Society for Neuro-Oncology Annual Meeting
Date:11/22/2013

dule, we expect to soon be delivering higher doses of VAL-083 and doing so more often."

Mr. Bacha added, "Although accelerating dose escalation is not expected to significantly alter the duration of the trial, we will treat fewer patients at sub-optimal doses and reach doses more likely to achieve meaningful patient benefit in a more cost efficient manner.  Importantly, we are proceeding on track to complete dose escalation and advance VAL-083 toward registration directed trials in refractory glioblastoma in the first half of 2014."

About VAL-083VAL-083 represents a first-in-class, small-molecule chemotherapeutic with a unique mechanism of action.  In more than 40 Phase 1 and Phase 2 clinical studies sponsored by the National Cancer Institute (NCI), VAL-083 has shown safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia.  VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.  As a potential treatment for glioblastoma, VAL-083's mechanism of action is unaffected by the expression of MGMT, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar (temozolomide).  DelMar is currently studying VAL-083 in a Phase 1/2 clinical trial for patients with refractory glioblastoma multiforme patients. 

About Glioblastoma Multiforme (GBM)Glioblastoma multiforme (GBM) is the most common and most malignant form of brain cancer. Approximately 15,000 people are diagnosed with glioblastoma each year in the U.S., with similar incidence in Europe. Standard of care is surgery, followed by radiation therapy or combined radiation therapy and chemotherapy with temozolomide.  Approximately 60 percent of GBM patients treated with temoz
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
2. DelMar Pharmaceuticals Gives Quarterly Shareholder Update
3. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
4. DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
5. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
6. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
7. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
8. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
9. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
10. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
11. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... , July 10, 2014 Decision Resources ... awareness of the U.S. Food and Drug Administration,s (FDA) ... phosphate binder Velphoro, which was approved by the FDA ... chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 : ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... LAGUNA HILLS, Calif., Oct. 6 Minnow Medical, Inc., ... thermoplasty for the treatment of in-stent restenosis and other ... veteran medical device executives. Prabodh Mathur ... K. Handley has been named vice president of quality, ...
... Oct. 6 Ferring Pharmaceuticals Inc. today announced ... trials of LYSTEDA™ (tranexamic acid) tablets for cyclic ... of the peer-reviewed journal, Obstetrics & Gynecology ... significantly reduced menstrual blood loss from baseline, and ...
Cached Medicine Technology:Minnow Medical Bolsters Management Team 2Minnow Medical Bolsters Management Team 3Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study 2Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study 3Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study 4
(Date:7/11/2014)... GA (PRWEB) July 11, 2014 Datalogic ... step in improving sanitation hospital wide. With their new ... the spread of disease, like the devastating MRSA, which ... The Gryphon GD4400-HC 2D and the Gryphon ... 2D barcodes and can even read barcodes off of ...
(Date:7/11/2014)... -- U.S. health officials have concluded that it,s highly ... during a safety mishap last month. But, the ... announced a moratorium on the transfer of any dangerous ... a report issued Friday, the CDC outlined several measures ... incident doesn,t occur again. Last month, as many as ...
(Date:7/11/2014)... enterprises today are shifting towards the changing trend in ... offer these global enterprises a strategic method to cut ... operational costs to companies. The aim to minimize operational ... market driver for expanding the managed services market in ... estimated to grow from $142.75 billion in 2013 to ...
(Date:7/11/2014)... 10, 2014) Obese and overweight firefighters are ... care providers, according to new research from The ... (UTHealth). , National guidelines state that health care ... of maintaining a healthy weight. Firefighters have high ... leading cause of line-of-duty deaths in firefighters. This ...
(Date:7/11/2014)... 11, 2014 (HealthDay News) -- Prostate cancer patients are ... less effective treatment and die sooner if they also ... data from more than 41,200 American men who were ... They followed them through 2009. Nearly 1,900 of the ... years before their prostate cancer was discovered. "Men ...
Breaking Medicine News(10 mins):Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Depression May Make It Harder to Beat Prostate Cancer 2
... Germany and America who had treated injured protestors while ... to // leave Nepal by the King Gyanendra's government. ... detained Wednesday after he appeared on a private television ... brutally assaulted by the security forces. ,On ...
... at the McDonald’s or KFC restaurants, across the world, have ... levels of the same // food elsewhere. ,According to ... of Medicine, the researchers analysed various food items like McDonald's ... in many countries between 2004 and 2005, the Associated Press ...
... that been launched on a trial basis in Singapore would ... intensive care unit//. A camera hooked up beside the baby's ... to view the live footage on 3G-enabled mobile phones, Singapore ... on a three-month trial, during which the infants go online ...
... symposium titled ‘Challenging Intellectual Property’ will be analyzed and ... ,The Symposium will look into the aspects of ... production in economic development. It will also gauge the ... table, desirous of bringing a change in health research ...
... way to reverse the process of cell division. This ... could be an important milestone in the fight// against ... from the Oklahoma Medical Research Foundation have published their ... a million times in the human body each day. ...
... If you thought that McDonalds’ in USA serves the same ... and// think!,According to a study by three Danish doctors, fat ... as "trans fat" in foods purchased at McDonald's Corp and ... to the staggering research published in this week's New England ...
Cached Medicine News:
Helmer's Horizon Series line of refrigerators are designed specifically for the cost conscious buyer. This line offers outstanding performance, quality, and the features you need to ensure the safety...
... presents i.Series refrigerators ... solutions for the blood ... features than ever before, ... are at the forefront ...
This storage freezer, which is based on our premium freezer line, maintain red cells safely below regulatory standards at -86C (-123F). Recorder is standard for model 8627. Model 8627 is UL Listed, C...
The TBR-360-1-GD is a large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standar...
Medicine Products: